
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Biotechnology · market cap $56M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| MaaT013 | Phase 3 | Acute Graft Versus Host Disease in Intestine |
| Autologous Fecal Microbiota Transplantation | Phase 2 | Leukemia, Myeloid, Acute |
| Pooled allogeneic fecal microbiotherapy | Phase 2 | Transplant Complication |
| fecal microbiota transfer | Phase 2 | Fecal Microbiota Transplantation |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.